Financière de Tubize SA TUB.BR Stock
Financière de Tubize SA Price Chart
Financière de Tubize SA TUB.BR Financial and Trading Overview
| Financière de Tubize SA stock price | 98.2 EUR |
| Previous Close | 74.3 EUR |
| Open | 74.7 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 74.7 - 75 EUR |
| 52 Week Range | 65.4 - 80.2 EUR |
| Volume | 497 EUR |
| Avg. Volume | 6.44K EUR |
| Market Cap | 3.4B EUR |
| Beta (5Y Monthly) | 0.477777 |
| PE Ratio (TTM) | 39.840427 |
| EPS (TTM) | 1.98 EUR |
| Forward Dividend & Yield | 0.86 (1.14%) |
| Ex-Dividend Date | May 3, 2023 |
| 1y Target Est | 92.9 EUR |
TUB.BR Valuation Measures
| Enterprise Value | 3.34B EUR |
| Trailing P/E | 39.840427 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 417342.16 |
| Price/Book (mrq) | 1.9059495 |
| Enterprise Value/Revenue | 409297.97 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Financière de Tubize SA Stock Price History
| Beta (5Y Monthly) | 0.477777 |
| 52-Week Change | -4.98% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 80.2 EUR |
| 52 Week Low | 65.4 EUR |
| 50-Day Moving Average | 75.83 EUR |
| 200-Day Moving Average | 72.61 EUR |
TUB.BR Share Statistics
| Avg. Volume (3 month) | 6.44K EUR |
| Avg. Daily Volume (10-Days) | 5.13K EUR |
| Shares Outstanding | 44.51M |
| Float | N/A |
| Short Ratio | N/A |
| % Held by Insiders | 56.88% |
| % Held by Institutions | 0.77% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.86 |
| Trailing Annual Dividend Yield | 1.15% |
| 5 Year Average Dividend Yield | 87.00% |
| Payout Ratio | 0.39200002 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 1044901.10% |
| Operating Margin (ttm) | -22362.69% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -0.063% |
| Return on Equity (ttm) | 4.92% |
Income Statement
| Revenue (ttm) | 8.15K EUR |
| Revenue Per Share (ttm) | 0 EUR |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | 85.17M EUR |
| Diluted EPS (ttm) | 1.88 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.07M EUR |
| Total Cash Per Share (mrq) | 0.02 EUR |
| Total Debt (mrq) | 47.8M EUR |
| Total Debt/Equity (mrq) | 2.73 EUR |
| Current Ratio (mrq) | 0.023 |
| Book Value Per Share (mrq) | 39.298 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -2110000 EUR |
| Levered Free Cash Flow (ttm) | -2365706 EUR |
Profile of Financière de Tubize SA
| Country | Belgium |
| State | N/A |
| City | Brussels |
| Address | Allee de la Recherche 60 |
| ZIP | 1070 |
| Phone | 32 497 51 52 08 |
| Website | https://www.financiere-tubize.be |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Q&A For Financière de Tubize SA Stock
What is a current TUB.BR stock price?
Financière de Tubize SA TUB.BR stock price today per share is 98.2 EUR.
How to purchase Financière de Tubize SA stock?
You can buy TUB.BR shares on the Brussels exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Financière de Tubize SA?
The stock symbol or ticker of Financière de Tubize SA is TUB.BR.
Which industry does the Financière de Tubize SA company belong to?
The Financière de Tubize SA industry is Biotechnology.
How many shares does Financière de Tubize SA have in circulation?
The max supply of Financière de Tubize SA shares is 44.51M.
What is Financière de Tubize SA Price to Earnings Ratio (PE Ratio)?
Financière de Tubize SA PE Ratio is 49.59596000 now.
What was Financière de Tubize SA earnings per share over the trailing 12 months (TTM)?
Financière de Tubize SA EPS is 1.98 EUR over the trailing 12 months.
Which sector does the Financière de Tubize SA company belong to?
The Financière de Tubize SA sector is Healthcare.